PASG (Passage Bio) 3-1 Month Momentum %: -54.33% (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PASG Passage Bio Inc PASG
30 GF Score
Price $4.83
! 2 Warning Signs
View Full Analysis

What is Passage Bio 3-1 Month Momentum %?

Passage Bio PASG -1.23% 30 3-1 Month Momentum % is -54.33% as of Jul. 19, 2026. GuruFocus rates PASG with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,387 Biotechnology companies, Passage Bio ranks worse than 96.32% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-19), Passage Bio's 3-1 Month Momentum % is -54.33%.

The industry rank for Passage Bio's 3-1 Month Momentum % or its related term are showing as below:

PASG's 3-1 Month Momentum % is ranked worse than
96.32% of 1387 companies
in the Biotechnology industry
Industry Median: -13.58 vs PASG: -54.33

Passage Bio  (NAS:PASG) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Passage Bio 3-1 Month Momentum % Related Terms

PASG vs CTXR, HIND, GTBP: 3-1 Month Momentum % Comparison

For the Biotechnology subindustry, Passage Bio's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Passage Bio 3-1 Month Momentum % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Passage Bio's 3-1 Month Momentum % falls into.


PASG
30GF Score
Passage Bio Inc PASG
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio  (NAS:PASG) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of -54.33% mean?
Passage Bio (PASG) has a 3-1 Month Momentum % of -54.33% as of Jul. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Passage Bio and its competitors. According to the industry distribution chart, Passage Bio ranks #1336 out of 1387 companies in the Biotechnology industry, placing it in the top 96.3%.
Is Passage Bio's 3-1 Month Momentum % too high?
Passage Bio's current 3-1 Month Momentum % is -54.33%. Based on the distribution chart, Passage Bio ranks #1336 out of 1387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Passage Bio has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's 3-1 Month Momentum % compare to CTXR and HIND?
According to the Biotechnology industry distribution chart, Passage Bio ranks #1336 out of 1387 companies for 3-1 Month Momentum %. This places Passage Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Passage Bio and its competitors. Passage Bio's current 3-1 Month Momentum % is -54.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current 3-1 Month Momentum % of -54.33%. The current 3-1 Month Momentum % is -54.33%. Passage Bio's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Passage Bio (PASG), the current 3-1 Month Momentum % is -54.33% as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
30GF Score

Get the complete analysis for PASG

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.83
Price